UroGen Pharma (FRA:UR8) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)

What is UroGen Pharma ROE % Adjusted to Book Value?

UroGen Pharma FRA:UR8 +0.88% 61 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 61/100 and a GF Value™ of €16.91 (Significantly Overvalued). The stock has 10 warning signs investors should review.

UroGen Pharma's ROE % for the quarter that ended in Mar. 2026 was 0.00%. UroGen Pharma's PB Ratio for the quarter that ended in Mar. 2026 was N/A. UroGen Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

UroGen Pharma ROE % Adjusted to Book Value Related Terms

UroGen Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma ROE % Adjusted to Book Value Chart

UroGen Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.31

0.00

UroGen Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:UR8 vs SEPN, FTRE, MLTX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, UroGen Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's ROE % Adjusted to Book Value falls into.

Save Embed

61GF Score

UroGen Pharma Ltd FRA:UR8

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

UroGen Pharma ROE % Adjusted to Book Value Calculation

UroGen Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

UroGen Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 0.00% mean?

UroGen Pharma (FRA:UR8) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on UroGen Pharma and its competitors.

Is UroGen Pharma's ROE % Adjusted to Book Value too high?

UroGen Pharma's current ROE % Adjusted to Book Value is 0.00%. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does UroGen Pharma's ROE % Adjusted to Book Value compare to SEPN and FTRE?

UroGen Pharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is UroGen Pharma stock overvalued right now?

Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.91, compared to a current price of €32.26 — trading 90.8% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €32.26 is trading 90.8% above its estimated GF Value™ of €16.91. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

ROE % Adjusted to Book Value: 0.00%
GF Value™: €16.91 vs. price of €32.26 (90.8% above fair value)
GF Score™: 61/100 with 10 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies SEPN FTRE MLTX VIR ZBIO AKTS INVA BCAX AVBP ZYME VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges URGN:USA 0XOD:UK

Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

61GF Score

Get the complete analysis for FRA:UR8

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.26

Price

€16.91

GF Value

View FRA:UR8 Analysis

See ROE % Adjusted to Book Value data for all stocks →